Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.

BTTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 51.40%

Insider Buying (Last 12 Months): $1,240,691.26

Insider Selling (Last 12 Months): $0.00

Better Therapeutics Insider Trading History Chart

Better Therapeutics Share Price & Price History

^$0.01

▼ -0.0009 (-9.00%)

As of 05/8/2024 05:16 PM ET

Days: 30 | 90 | 365

BREAKING – Pentagon to Spend $20 Billion on “Distributed AI”

From Behind the Markets | Ad

BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.

Discover the name and ticker of this $2 stock here >>>

Better Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/27/2023	Andrew J. Armanino	Director	Buy	274,010	$0.73	$200,027.30	728,368
7/27/2023	David P Perry	Chairman	Buy	1,233,045	$0.73	$900,122.85	13,030,393
7/27/2023	Frank Karbe	CEO	Buy	137,005	$0.73	$100,013.65	429,429
7/27/2023	Mark A Berman	Insider	Buy	54,802	$0.73	$40,005.46	388,191
5/16/2023	Elder Granger	Director	Buy	600	$0.87	$522.00	1,600
4/10/2023	Frank Karbe	Insider	Buy	242,424	$0.82	$198,787.68	292,424
4/10/2023	Geoffrey M Parker	Director	Buy	303,030	$0.82	$248,484.60	343,030
9/15/2022	Frank Karbe	Insider	Buy	50,000	$2.09	$104,500.00	50,000
9/12/2022	Mark Heinen	Insider	Buy	23,868	$1.94	$46,303.92	43,868
6/24/2022	Mark Heinen	Insider	Buy	2,281	$1.75	$3,991.75	2,281
6/13/2022	Geoffrey M Parker	Director	Buy	25,000	$1.45	$36,250.00	40,000
6/10/2022	Mark Heinen	Insider	Buy	5,000	$1.56	$7,800.00	20,000
3/31/2022	Kevin J. Appelbaum	CEO	Buy	2,500	$1.97	$4,925.00	6,250
3/31/2022	Mark Heinen	Insider	Buy	5,000	$1.98	$9,900.00	15,000
3/29/2022	Andrew J. Armanino	Director	Buy	40,000	$2.14	$85,600.00
12/21/2021	Risa J. Lavizzo-Mourey	Director	Buy	10,000	$4.60	$46,000.00
12/20/2021	Kevin J. Appelbaum	CEO	Buy	1,000	$4.60	$4,600.00
12/15/2021	Kevin J. Appelbaum	CEO	Buy	750	$4.71	$3,532.50
12/15/2021	Mark Heinen	Insider	Buy	2,333	$4.70	$10,965.10
12/13/2021	Andrew J. Armanino	Director	Buy	21,000	$5.48	$115,080.00
12/13/2021	Mark Heinen	Insider	Buy	500	$5.45	$2,725.00
12/10/2021	Kevin J. Appelbaum	CEO	Buy	1,000	$5.98	$5,980.00
12/3/2021	Elder Granger	Director	Buy	1,000	$6.66	$6,660.00
12/2/2021	Kevin J. Appelbaum	CEO	Buy	500	$6.84	$3,420.00
11/29/2021	Andrew J. Armanino	Director	Buy	17,000	$6.96	$118,320.00

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

SEC Filings (Institutional Ownership Changes) for Better Therapeutics (NASDAQ:BTTX)

34.00% of Better Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Better Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/12/2024	MMCAP International Inc. SPC	356,270	$65K	0.0%	-77.5%	0.715%
11/14/2023	MMCAP International Inc. SPC	1,583,079	$0.58M	0.2%	N/A	3.340%
5/15/2023	Farallon Capital Management LLC	699,042	$0.51M	0.0%	-14.1%	2.931%
5/10/2022	Sectoral Asset Management Inc.	878,531	$1.74M	0.3%	-9.8%	3.721%
5/4/2022	Victory Capital Management Inc.	272,720	$0.54M	0.0%	N/A	1.155%

Data available starting January 2016

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Today's Range

Now: $0.01

$0.01

$0.02

50 Day Range

MA: $0.05

$0.01

$0.22

52 Week Range

Now: $0.01

$0.01

$1.35

Volume

107,909 shs

Average Volume

4,815,302 shs

Market Capitalization

$453,726.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Who are the company insiders with the largest holdings of Better Therapeutics?: Better Therapeutics' top insider shareholders include:
David P Perry (Chairman)
Andrew J Armanino (Director)
Frank Karbe (CEO)
Mark A Berman (Insider)
Geoffrey M Parker (Director)
Frank Karbe (Insider)
Mark Heinen (Insider)
Elder Granger (Director)
Learn More about top insider investors at Better Therapeutics.